A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies

NCT05796570 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes
Myeloid Malignancies
MDS
Inherited Bone Marrow Failure Syndrome
Myeloid Neoplasm
Aml

Interventions

DRUG: Decitabine
DRUG: Filgrastim

Sponsor

Franziska Wachter

Collaborators

Harvard Clinical and Translational Science Center (Harvard Catalyst)